Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 202

1.

Viral suppression and HIV transmission behaviors among hospitalized patients living with HIV.

Pan Y, Metsch LR, Gooden LK, Philbin MM, Daar ES, Douaihy A, Jacobs P, Del Rio C, Rodriguez AE, Feaster DJ.

Int J STD AIDS. 2019 Aug;30(9):891-901. doi: 10.1177/0956462419846726. Epub 2019 Jun 3. No abstract available.

PMID:
31159715
2.

Progressive brain atrophy in chronically infected and treated HIV+ individuals.

Nir TM, Jahanshad N, Ching CRK, Cohen RA, Harezlak J, Schifitto G, Lam HY, Hua X, Zhong J, Zhu T, Taylor MJ, Campbell TB, Daar ES, Singer EJ, Alger JR, Thompson PM, Navia BA; HIV Neuroimaging Consortium.

J Neurovirol. 2019 Jun;25(3):342-353. doi: 10.1007/s13365-019-00723-4. Epub 2019 Feb 14.

PMID:
30767174
3.

Clinical and Sociobehavioral Prediction Model of 30-Day Hospital Readmissions Among People With HIV and Substance Use Disorder: Beyond Electronic Health Record Data.

Nijhawan AE, Metsch LR, Zhang S, Feaster DJ, Gooden L, Jain MK, Walker R, Huffaker S, Mugavero MJ, Jacobs P, Armstrong WS, Daar ES, Sullivan M, Del Rio C, Halm EA.

J Acquir Immune Defic Syndr. 2019 Mar 1;80(3):330-341. doi: 10.1097/QAI.0000000000001925.

PMID:
30763292
4.

Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202.

Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Acosta EP, Mager DE, Morse GD; AIDS Clinical Trials Group Study A5202 Team.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e01638-18. doi: 10.1128/AAC.01638-18. Print 2019 Apr.

PMID:
30642925
5.

Generalizing Evidence from Randomized Trials using Inverse Probability of Sampling Weights.

Buchanan AL, Hudgens MG, Cole SR, Mollan KR, Sax PE, Daar ES, Adimora AA, Eron JJ, Mugavero MJ.

J R Stat Soc Ser A Stat Soc. 2018 Oct;181(4):1193-1209. doi: 10.1111/rssa.12357. Epub 2018 Feb 26.

PMID:
30555215
6.

Relationships Between Adipose Mitochondrial Function, Serum Adiponectin, and Insulin Resistance in Persons With HIV After 96 Weeks of Antiretroviral Therapy.

Hulgan T, Ramsey BS, Koethe JR, Samuels DC, Gerschenson M, Libutti DE, Sax PE, Daar ES, McComsey GA, Brown TT.

J Acquir Immune Defic Syndr. 2019 Mar 1;80(3):358-366. doi: 10.1097/QAI.0000000000001926.

PMID:
30531304
7.

Two-drug regimens for treatment of naïve HIV-1 infection and as maintenance therapy.

Corado KC, Caplan MR, Daar ES.

Drug Des Devel Ther. 2018 Nov 1;12:3731-3740. doi: 10.2147/DDDT.S140767. eCollection 2018. Review.

8.

Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1.

Hoenigl M, Jain S, Moore D, Collins D, Sun X, Anderson PL, Corado K, Blumenthal JS, Daar ES, Milam J, Dubé MP, Morris S; California Collaborative Treatment Group 595 Team.

Emerg Infect Dis. 2018 Dec;24(12). doi: 10.3201/eid2412.180400.

9.

Sexual Risk Compensation in a Pre-exposure Prophylaxis Demonstration Study Among Individuals at Risk of HIV.

Milam J, Jain S, Dubé MP, Daar ES, Sun X, Corado K, Ellorin E, Blumenthal J, Haubrich R, Moore DJ, Morris SR; CCTG Team.

J Acquir Immune Defic Syndr. 2019 Jan 1;80(1):e9-e13. doi: 10.1097/QAI.0000000000001885.

PMID:
30334877
10.

Antiretroviral switch studies do matter.

Daar ES, Ruane P, DeJesus E, Stellbrink HJ, Molina JM.

Lancet HIV. 2018 Oct;5(10):e546. doi: 10.1016/S2352-3018(18)30259-5. Epub 2018 Oct 8. No abstract available.

PMID:
30319119
11.

Trajectories and Predictors of Longitudinal Preexposure Prophylaxis Adherence Among Men Who Have Sex With Men.

Pasipanodya EC, Jain S, Sun X, Blumenthal J, Ellorin E, Corado K, Dube MP, Daar ES, Morris SR, Moore DJ; California Collaborative Treatment Group (CCTG) TAPIR Study Team.

J Infect Dis. 2018 Oct 5;218(10):1551-1559. doi: 10.1093/infdis/jiy368.

PMID:
30295803
12.

Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood.

Yang J, Nikanjam M, Best BM, Pinto J, Chadwick EG, Daar ES, Havens PL, Rakhmanina N, Capparelli EV.

J Clin Pharmacol. 2018 Dec;58(12):1604-1617. doi: 10.1002/jcph.1293. Epub 2018 Sep 25.

PMID:
30252146
13.

Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314.

Hsue PY, Ribaudo HJ, Deeks SG, Bell T, Ridker PM, Fichtenbaum C, Daar ES, Havlir D, Yeh E, Tawakol A, Lederman M, Currier JS, Stein JH.

Clin Infect Dis. 2019 May 17;68(11):1877-1886. doi: 10.1093/cid/ciy781.

PMID:
30219823
14.

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.

Hagins D, Orkin C, Daar ES, Mills A, Brinson C, DeJesus E, Post FA, Morales-Ramirez J, Thompson M, Osiyemi O, Rashbaum B, Stellbrink HJ, Martorell C, Liu H, Liu YP, Porter D, Collins SE, SenGupta D, Das M.

HIV Med. 2018 Nov;19(10):724-733. doi: 10.1111/hiv.12664. Epub 2018 Aug 12.

15.

CD8+ Cytotoxic T Lymphocyte Responses and Viral Epitope Escape in Acute HIV-1 Infection.

Kim J, De La Cruz J, Lam K, Ng H, Daar ES, Balamurugan A, Yang OO.

Viral Immunol. 2018 Sep;31(7):525-536. doi: 10.1089/vim.2018.0040. Epub 2018 Jul 30.

PMID:
30059271
16.

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.

Daar ES, DeJesus E, Ruane P, Crofoot G, Oguchi G, Creticos C, Rockstroh JK, Molina JM, Koenig E, Liu YP, Custodio J, Andreatta K, Graham H, Cheng A, Martin H, Quirk E.

Lancet HIV. 2018 Jul;5(7):e347-e356. doi: 10.1016/S2352-3018(18)30091-2. Epub 2018 Jun 18.

PMID:
29925490
17.

Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events.

Haas DW, Bradford Y, Verma A, Verma SS, Eron JJ, Gulick RM, Riddler SA, Sax PE, Daar ES, Morse GD, Acosta EP, Ritchie MD.

Pharmacogenet Genomics. 2018 Jul;28(7):179-187. doi: 10.1097/FPC.0000000000000341.

18.

Randomized Trial of a Health Coaching Intervention to Enhance Retention in Care: California Collaborative Treatment Group 594.

Corado K, Jain S, Morris S, Dube MP, Daar ES, He F, Aldous JL, Sitapati A, Haubrich R, Milam J, Karris MY.

AIDS Behav. 2018 Aug;22(8):2698-2710. doi: 10.1007/s10461-018-2132-3.

19.

Next generation fixed dose combination pharmacotherapies for treating HIV.

Caplan MR, Daar ES, Corado KC.

Expert Opin Pharmacother. 2018 Apr;19(6):589-596. doi: 10.1080/14656566.2018.1450866. Epub 2018 Mar 20. Review.

PMID:
29557204
20.

Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study.

Moore DJ, Jain S, Dubé MP, Daar ES, Sun X, Young J, Corado K, Ellorin E, Milam J, Collins D, Blumenthal J, Best BM, Anderson P, Haubrich R, Morris SR.

Clin Infect Dis. 2018 May 2;66(10):1566-1572. doi: 10.1093/cid/cix1055.

21.

Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.

Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Yang Y, Wilding GE, Morse GD.

Ther Drug Monit. 2017 Dec;39(6):596-603. doi: 10.1097/FTD.0000000000000443.

22.

Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection.

Winhusen T, Feaster DJ, Duan R, Brown JL, Daar ES, Mandler R, Metsch LR.

AIDS Behav. 2018 Jun;22(6):2026-2032. doi: 10.1007/s10461-017-1928-x.

23.

Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants.

Mollan KR, Tierney C, Hellwege JN, Eron JJ, Hudgens MG, Gulick RM, Haubrich R, Sax PE, Campbell TB, Daar ES, Robertson KR, Ventura D, Ma Q, Edwards DRV, Haas DW; AIDS Clinical Trials Group.

J Infect Dis. 2017 Sep 1;216(5):554-564. doi: 10.1093/infdis/jix248.

24.

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.

Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E.

Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31.

PMID:
28867497
25.

Novel approaches to HIV therapy.

Daar ES.

F1000Res. 2017 May 31;6:759. doi: 10.12688/f1000research.11164.1. eCollection 2017. Review.

26.

Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study.

Wyles D, Bräu N, Kottilil S, Daar ES, Ruane P, Workowski K, Luetkemeyer A, Adeyemi O, Kim AY, Doehle B, Huang KC, Mogalian E, Osinusi A, McNally J, Brainard DM, McHutchison JG, Naggie S, Sulkowski M; ASTRAL-5 Investigators.

Clin Infect Dis. 2017 Jul 1;65(1):6-12. doi: 10.1093/cid/cix260.

27.

Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study.

Parker RA, Rabideau DJ, Sax PE, Tierney C, Daar ES, Collier AC, Losina E, Freedberg KA.

Clin Infect Dis. 2017 Jun 1;64(11):1612-1614. doi: 10.1093/cid/cix176.

28.

Emtricitabine + tenofovir alafenamide for the treatment of HIV.

Corado KC, Daar ES.

Expert Opin Pharmacother. 2017 Mar;18(4):427-432. doi: 10.1080/14656566.2017.1288720. Epub 2017 Feb 8. Review.

PMID:
28151023
29.

HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimen.

Karris MY, Jain S, Day TR, Pérez-Santiago J, Goicoechea M, Dubé MP, Sun X, Spina C, Daar ES, Haubrich RH, Morris S; California Collaborative Treatment Group (CCTG) 589 Study Team.

HIV Clin Trials. 2017 Mar;18(2):67-74. doi: 10.1080/15284336.2017.1282578. Epub 2017 Jan 30.

30.

Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202.

Verma A, Bradford Y, Verma SS, Pendergrass SA, Daar ES, Venuto C, Morse GD, Ritchie MD, Haas DW.

Pharmacogenet Genomics. 2017 Mar;27(3):101-111. doi: 10.1097/FPC.0000000000000263.

31.

Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use: A Randomized Clinical Trial.

Metsch LR, Feaster DJ, Gooden L, Matheson T, Stitzer M, Das M, Jain MK, Rodriguez AE, Armstrong WS, Lucas GM, Nijhawan AE, Drainoni ML, Herrera P, Vergara-Rodriguez P, Jacobson JM, Mugavero MJ, Sullivan M, Daar ES, McMahon DK, Ferris DC, Lindblad R, VanVeldhuisen P, Oden N, Castellón PC, Tross S, Haynes LF, Douaihy A, Sorensen JL, Metzger DS, Mandler RN, Colfax GN, del Rio C.

JAMA. 2016 Jul 12;316(2):156-70. doi: 10.1001/jama.2016.8914.

32.

Condomless Sex With Virologically Suppressed HIV-Infected Individuals: How Safe Is It?

Daar ES, Corado K.

JAMA. 2016 Jul 12;316(2):149-51. doi: 10.1001/jama.2016.5636. No abstract available.

PMID:
27404181
33.

Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.

Borges ÁH, Lundh A, Tendal B, Bartlett JA, Clumeck N, Costagliola D, Daar ES, Echeverría P, Gisslén M, Huedo-Medina TB, Hughes MD, Huppler Hullsiek K, Khabo P, Komati S, Kumar P, Lockman S, MacArthur RD, Maggiolo F, Matteelli A, Miro JM, Oka S, Petoumenos K, Puls RL, Riddler SA, Sax PE, Sierra-Madero J, Torti C, Lundgren JD.

Clin Infect Dis. 2016 Jul 15;63(2):268-80. doi: 10.1093/cid/ciw236. Epub 2016 Apr 18. Review.

34.

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.

Gallant JE, Daar ES, Raffi F, Brinson C, Ruane P, DeJesus E, Johnson M, Clumeck N, Osiyemi O, Ward D, Morales-Ramirez J, Yan M, Abram ME, Plummer A, Cheng AK, Rhee MS.

Lancet HIV. 2016 Apr;3(4):e158-65. doi: 10.1016/S2352-3018(16)00024-2. Epub 2016 Mar 14.

PMID:
27036991
35.

Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.

Karris MY, Jain S, Bowman VQ, Rieg G, Goicoechea M, Dube MP, Kerkar S, Kemper C, Diamond C, Sun X, Daar ES, Haubrich RH, Morris S; California Collaborative Treatment Group (CCTG) 589 Study Team.

J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):e48-50. doi: 10.1097/QAI.0000000000000990. No abstract available.

36.

Brief Report: Effect of CMV and HIV Transcription on CD57 and PD-1 T-Cell Expression During Suppressive ART.

Dan JM, Massanella M, Smith DM, Spina CA, Schrier R, Daar ES, Dube MP, Morris SR, Gianella S.

J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):133-7. doi: 10.1097/QAI.0000000000000936.

37.

Genital Epstein Barr Virus is associated with higher prevalence and persistence of anal human papillomavirus in HIV-infected men on antiretroviral therapy.

Gianella S, Ginocchio CC, Daar ES, Dube MP, Morris SR.

BMC Infect Dis. 2016 Jan 25;16:24. doi: 10.1186/s12879-016-1356-y.

38.

Distinct cytokine/chemokine network in semen and blood characterize different stages of HIV infection.

Vanpouille C, Introini A, Morris SR, Margolis L, Daar ES, Dube MP, Little SJ, Smith DM, Lisco A, Gianella S.

AIDS. 2016 Jan;30(2):193-201. doi: 10.1097/QAD.0000000000000964.

39.

Randomized Controlled Trial of an Internet Application to Reduce HIV Transmission Behavior Among HIV Infected Men Who have Sex with Men.

Milam J, Morris S, Jain S, Sun X, Dubé MP, Daar ES, Jimenez G, Haubrich R; CCTG 592 Team.

AIDS Behav. 2016 Jun;20(6):1173-1181. doi: 10.1007/s10461-015-1215-7.

40.

Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy.

Massanella M, Gianella S, Schrier R, Dan JM, Pérez-Santiago J, Oliveira MF, Richman DD, Little SJ, Benson CA, Daar ES, Dube MP, Haubrich RH, Smith DM, Morris SR.

Sci Rep. 2015 Aug 24;5:13179. doi: 10.1038/srep13179.

41.

Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202.

Wanga V, Venuto C, Morse GD, Acosta EP, Daar ES, Haas DW, Li C, Shepherd BE.

Pharmacogenet Genomics. 2015 Sep;25(9):450-61. doi: 10.1097/FPC.0000000000000156.

42.

Genital Cytomegalovirus Replication Predicts Syphilis Acquisition among HIV-1 Infected Men Who Have Sex with Men.

Gianella S, Smith DM, Daar ES, Dube MP, Lisco A, Vanpouille C, Margolis L, Haubrich RH, Morris SR.

PLoS One. 2015 Jun 10;10(6):e0130410. doi: 10.1371/journal.pone.0130410. eCollection 2015.

43.

Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s.

Longenecker CT, Kitch D, Sax PE, Daar ES, Tierney C, Gupta SK, McComsey GA; AIDS Clinical Trials Group Study A5224s Team.

J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):168-77. doi: 10.1097/QAI.0000000000000557.

44.

Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols.

Moore CB, Verma A, Pendergrass S, Verma SS, Johnson DH, Daar ES, Gulick RM, Haubrich R, Robbins GK, Ritchie MD, Haas DW.

Open Forum Infect Dis. 2015 Jan 9;2(1):ofu113. doi: 10.1093/ofid/ofu113. eCollection 2015 Jan.

45.

A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens.

Broglio KR, Daar ES, Quintana M, Yuan Y, Kalsekar A, Spellberg B, Lewis RJ, Akker Dv, Detry MA, Le T, Berry SM.

J Comp Eff Res. 2015 Mar;4(2):101-14. doi: 10.2217/cer.14.69. Review.

PMID:
25825840
46.

Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial.

Gupta SK, Kitch D, Tierney C, Daar ES, Sax PE, Melbourne K, Ha B, McComsey GA; AIDS Clinical Trials Group Study A5224s Team.

Open Forum Infect Dis. 2014 Apr 16;1(1):ofu003. doi: 10.1093/ofid/ofu003. eCollection 2014 Mar.

47.

A Remotely-Delivered CBT and Contingency Management Therapy for Substance Using People with HIV.

Moore BA, Rosen MI, Wang Y, Shen J, Ablondi K, Sullivan A, Guerrero M, Siqueiros L, Daar ES, Liu H.

AIDS Behav. 2015 Jun;19 Suppl 2:156-62. doi: 10.1007/s10461-014-0990-x.

48.

Plasma and Cerebrospinal Fluid Biomarkers Predict Cerebral Injury in HIV-Infected Individuals on Stable Combination Antiretroviral Therapy.

Anderson AM, Harezlak J, Bharti A, Mi D, Taylor MJ, Daar ES, Schifitto G, Zhong J, Alger JR, Brown MS, Singer EJ, Campbell TB, McMahon DD, Buchthal S, Cohen R, Yiannoutsos C, Letendre SL, Navia BA; HIV Neuroimaging Consortium.

J Acquir Immune Defic Syndr. 2015 May 1;69(1):29-35. doi: 10.1097/QAI.0000000000000532.

49.

Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.

Lehmann DS, Ribaudo HJ, Daar ES, Gulick RM, Haubrich RH, Robbins GK, de Bakker PI, Haas DW, McLaren PJ.

Pharmacogenet Genomics. 2015 Feb;25(2):51-9. doi: 10.1097/FPC.0000000000000106.

50.

Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.

Venuto CS, Mollan K, Ma Q, Daar ES, Sax PE, Fischl M, Collier AC, Smith KY, Tierney C, Morse GD.

J Antimicrob Chemother. 2014 Dec;69(12):3300-10. doi: 10.1093/jac/dku303. Epub 2014 Aug 25.

Supplemental Content

Support Center